Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms25010211 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Anastasia Ryapolova und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gene Therapy, Sirius University of Science and Technology, Olympic Avenue, 1, 354340 Sochi, Russia. Hauptthemen laut MEDLINE: Immunotherapy, Melanoma, Experimental. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.
Abstract (Originalsprache)
Anti-cancer therapy based on oncolytic viruses (OVs) is a targeted approach that takes advantage of OVs’ ability to selectively infect and replicate in tumor cells, activate the host immune response, and destroy malignant cells over healthy ones. Vesicular stomatitis virus (VSV) is known for its wide range of advantages: a lack of pre-existing immunity, a genome that is easily amenable to manipulation, and rapid growth to high titers in a broad range of cell lines, to name a few. VSV-induced tumor immunity can be enhanced by the delivery of immunostimulatory cytokines. The targeted cytokine delivery to tumors avoids the significant toxicity associated with systemic delivery while also boosting the immune response. To demonstrate this enhanced effect on both tumor growth and survival, a novel recombinant VSV (rVSV)-mIL12-mGMCSF, co-expressing mouse IL-12 (interleukin-12) and GM-CSF (granulocyte-macrophage colony-stimulating factor), was tested alongside rVSV-dM51-GFP (rVSV-GFP) that was injected intratumorally in a syngeneic in vivo C57BL/6 mouse model infused subcutaneously with B16-F10 melanoma cells. The pilot study tested the effect of two viral injections 4 days apart and demonstrated that treatment with the two rVSVs resulted in partial inhibition of tumor growth (TGII of around 40%) and an increased survival rate in animals from the treatment groups. The effect of the two VSVs on immune cell populations will be investigated in future in vivo studies with an optimized experimental design with multiple higher viral doses, as a lack of this information presents a limitation of this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gene Therapy, Sirius University of Science and Technology, Olympic Avenue, 1, 354340 Sochi, Russia.
- Department of Molecular Virology, First Moscow State Medical University (Sechenov University), 20 Pirogovskaya, 119991 Moscow, Russia.
ORCID-Profile: Anastasia Ryapolova, Ekaterina Minskaia, Nizami Gasanov, Alexander D Egorov, Elena Subcheva, Roman Ivanov, Alexander Karabelsky
Förderung
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Ryapolova, A., Minskaia, E., Gasanov, N., Moroz, V., Krapivin, B., Egorov, A. D., Laktyushkin, V., Zhuravleva, S., Nagornych, M., Subcheva, E., Malogolovkin, A., Ivanov, R., & Karabelsky, A. (2023). Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25010211
Vancouver
Ryapolova A, Minskaia E, Gasanov N, Moroz V, Krapivin B, Egorov AD, et al. Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms25010211
BibTeX
@article{Ryapolova2023,
author = {Ryapolova, Anastasia and Minskaia, Ekaterina and Gasanov, Nizami and Moroz, Vasiliy and Krapivin, Bogdan and Egorov, Alexander D and Laktyushkin, Victor and Zhuravleva, Sofia and Nagornych, Maksim and Subcheva, Elena and Malogolovkin, Alexander and Ivanov, Roman and Karabelsky, Alexander},
title = {Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms25010211}
}
EUVIMED